FDA OKs Sanofi diabetes drug in newly diagnosed pediatric patients
The FDA has granted accelerated approval to Sanofi's Tzield for delaying insulin decline in newly diagnosed pediatric type 1 diabetes patients. The approval is based on the PROTECT phase 3 study showing a 0.13 pmol/mL difference in C-peptide levels versus placebo. Continued approval depends on confirmatory trials, including the ongoing BETA-PRESERVE study.
*this image is generated using AI for illustrative purposes only.
The US Food and Drug Administration (FDA) has granted accelerated approval to Sanofi 's Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in children ages 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This approval marks the first disease-modifying therapy for this specific patient population, addressing a critical unmet medical need for approximately 64,000 people diagnosed annually. The therapy is not indicated for non-autoimmune dysglycemic conditions.
The regulatory decision was supported by data from the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield. The study evaluated beta cell function by measuring the decrease in mean C-peptide levels. The study demonstrated a statistically significant difference in least-squares means of 0.13 pmol/mL (95% confidence interval: 0.09-0.17; p<0.001) at trial completion compared to placebo. Adverse events observed in the study were consistent with previous findings, with common reactions including lymphopenia, vomiting, rash, and leukopenia.
PROTECT Phase 3 Study Details
The PROTECT study was a randomized, double-blind, placebo-controlled, multinational trial involving 328 children and adolescents aged eight to 17. Participants were diagnosed with clinical stage 3 T1D within the preceding six weeks and were randomized in a 2:1 ratio to receive either Tzield or placebo. The regimen consisted of an initial course of 12 daily infusions, followed by a second course of 12 daily infusions after 26 weeks, alongside standard-of-care medicines.
| Category | Details |
|---|---|
| Study Identifier | NCT03875729 |
| Participants (Tzield/Placebo) | 217 / 111 |
| Age Group | 8 to 17 years |
| Primary Endpoint | Change in C-peptide levels |
| LS Mean Difference | 0.13 pmol/mL |
Regulatory Status and Safety
This indication is granted under accelerated approval based on evidence of reduced C-peptide decline, a surrogate endpoint reasonably likely to predict clinical benefit. Consequently, continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory studies. The confirmatory BETA-PRESERVE phase 3 study (NCT07088068) has been initiated and is currently enrolling participants.
Serious adverse events reported with Tzield include cytokine release syndrome and life-threatening cases of viral reactivation, particularly in immunocompromised patients. Prior to this approval, the FDA expanded the indication in April 2026 to delay the onset of stage 3 T1D in adults and children eight years and older with stage 2 T1D to include children aged one year and above. Tzield is also approved in the UK, the EU, China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil, and Switzerland to delay the onset of stage 3 T1D in patients with stage 2 T1D.
Historical Stock Returns for Sanofi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.84% | +1.70% | +0.15% | -23.61% | -47.50% | -58.54% |
What are the projected peak sales estimates for Tzield given the expansion into the pediatric stage 3 market?
How will the requirement for confirmatory trials impact the timeline for full FDA approval?
What pricing strategies will Sanofi employ to ensure broad insurance coverage for this new indication?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
